RxDoctor Payments Data

Gordhan Diora, MD

Internal Medicine · Sterling Heights, MINPI 1902896731

Payments from drug & device makers

$7,448in general payments, 2019–2025

Across 455 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$674
  • AbbVie$526
  • Amgen$509
  • Pfizer$462
  • Lilly USA, LLC$328
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$7,437100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,448 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$211,512
Medicare patients
266
Services billed
3,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$125,789
EliquisApixaban73$88,449
TrulicityDulaglutide45$74,055
JardianceEmpagliflozin57$67,581
OzempicSemaglutide28$55,579
XareltoRivaroxaban26$31,890
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$28,943
RybelsusSemaglutide14$24,352
JanuviaSitagliptin Phosphate17$19,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,131
Repatha SureclickEvolocumab17$15,319
Soliqua 100-33Insulin Glargine/Lixisenatide12$13,912
FarxigaDapagliflozin Propanediol11$13,393
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$12,934
Atorvastatin Calcium765$10,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$328$199,843123 claims
PfizerEliquis$462$88,44973 claims
Novo NordiskOzempic, Rybelsus$1,062$79,93142 claims
Boehringer IngelheimJardiance$66$67,58157 claims
Johnson & JohnsonXarelto$148$31,89026 claims
GSKTrelegy Ellipta, Anoro Ellipta$674$31,06452 claims
MerckJanuvia$126$19,75917 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$270$13,91212 claims
AstraZenecaFarxiga$320$13,39311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →